GDTC
CytoMed Therapeutics Ltd (GDTC)
Healthcare • NASDAQ • $0.78+7.85%
- Symbol
- GDTC
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.78
- Daily Change
- +7.85%
- Market Cap
- $9.23M
- Trailing P/E
- N/A
- Forward P/E
- -5.20
- 52W High
- $3.68
- 52W Low
- $0.68
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- -0.17
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable al…
Company websiteResearch GDTC on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.